Category: Pharma, Life Sciences & Med Tech Players
-
PI spate: Novo Nordisk just obtained 29 injunctions (26 over patent, 3 over UCL) against semaglutide rivals in Germany, served at CPHI fair
Context: What’s new: Novo Nordisk has just obtained, served and enforced a whopping 29 preliminary injunctions (PIs) against (mostly Asian and to a lesser extent European) companies offering the active pharmaceutical ingredient semaglutide and/or pharmaceuticals containing semaglutide at the CPHI fair. The pan-European law firm of Hoyng Rokh Monegier, in collaboration with UK firm Bristows,…
-
Munich I Regional Court’s written reasons for multi-country pharma PI: out-of-district defendants can be sued, German procedures apply
The Munich I Regional Court’s headnotes are highly instructive and make the court an attractive forum for cross-border injunctions.
-
Pharma patent litigation updates: Boehringer, Orion, Pfizer, Kaleo file fresh patent infringement suits in District of Delaware
The District of Delaware continues to receive a substantial volume of pharmaceutical patent infringement complaints, with an arthritis-related Pfizer suit and diabetes-related Boehringer suit among the latest.
-
Munich I Regional Court’s stunning PI for 20+ countries: based on BSH, doctrine of equivalents, difficult-to-enforce formulation patent
Munich has been a patent injunction hotspot for many years, and the latest development may attract even more litigation to the venue.
-
AstraZeneca faces fresh mRNA patent infringement allegations in District of Delaware
Gene-editing tech company Factor Bioscience has sued AstraZeneca and its affiliate Cellectis over the infringement of three mRNA-related patents.
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.
-
Doctrine of equivalents removes painkiller from German market: Grünenthal wins preliminary injunction on appeal
A pharma patent and unfair competition dispute has taken a remarkable turn as the Dusseldorf Higher Regional Court granted a preliminary injunction based on infringement by equivalents.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.
-
Pharma and Biotech Patent Litigation Summit Europe returns in 2026: rebranded event features tech industry track, UPC litigation forum
Kisaco Research’s annual Pharma and Biotech Patent Litigation Summit Europe will take place from January 19 to January 21 in the Beurs van Berlage, Amsterdam, with ip fray as an official media partner.